"Antiparkinson Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
| Descriptor ID |
D000978
|
| MeSH Number(s) |
D27.505.954.427.090.050
|
| Concept/Terms |
Antiparkinson Agents- Antiparkinson Agents
- Agents, Antiparkinson
- Antiparkinsonian Agents
- Agents, Antiparkinsonian
- Antiparkinsonians
- Antiparkinson Drugs
- Drugs, Antiparkinson
|
Below are MeSH descriptors whose meaning is more general than "Antiparkinson Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiparkinson Agents".
This graph shows the total number of publications written about "Antiparkinson Agents" by people in this website by year, and whether "Antiparkinson Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 3 | 2 | 5 |
| 2000 | 1 | 1 | 2 |
| 2001 | 2 | 2 | 4 |
| 2002 | 3 | 1 | 4 |
| 2004 | 2 | 0 | 2 |
| 2005 | 3 | 2 | 5 |
| 2006 | 4 | 1 | 5 |
| 2007 | 1 | 5 | 6 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 1 | 3 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 2 | 4 |
| 2015 | 1 | 2 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 3 | 4 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiparkinson Agents" by people in Profiles.
-
Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med. 2022 08 04; 387(5):421-432.
-
Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease. Expert Rev Neurother. 2022 06; 22(6):489-498.
-
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson's disease brain. Mol Neurodegener. 2021 05 05; 16(1):31.
-
Parkinson's disease and skin. Parkinsonism Relat Disord. 2021 01; 82:61-76.
-
Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study. J Neural Transm (Vienna). 2021 02; 128(2):273-277.
-
Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020 08; 91(8):795-808.
-
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol. 2020 04 01; 38(10):1019-1029.
-
Multilevel Features for Sensor-Based Assessment of Motor Fluctuation in Parkinson's Disease Subjects. IEEE J Biomed Health Inform. 2020 05; 24(5):1284-1295.
-
Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord. 2019 10; 67:74-89.
-
Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease? Nat Rev Neurol. 2017 Nov; 13(11):643-644.